PVL (Panton-Valentine leukocidin) and other Staphylococcus aureus β-stranded pore-forming toxins are important virulence factors involved in various pathologies that are often necrotizing. The present study characterized leukotoxin inhibition by selected SCns (p-sulfonato-calix[n]arenes): SC4, SC6 and SC8. These chemicals have no toxic effects on human erythrocytes or neutrophils, and some are able to inhibit both the activity of and the cell lysis by leukotoxins in a dose-dependent manner. Depending on the type of leukotoxins and SCns, flow cytometry revealed IC 50 values of 6-22 μM for Ca 2 + activation and of 2-50 μM for cell lysis. SCns were observed to affect membrane binding of class S proteins responsible for cell specificity. Electrospray MS and surface plasmon resonance established supramolecular interactions (1:1 stoichiometry) between SCns and class S proteins in solution, but not class F proteins. The membrane-binding affinity of S proteins was K d = 0.07-6.2 nM. The binding ability was completely abolished by SCns at different concentrations according to the number of benzenes (30-300 μM; SC8>SC6 SC4). The inhibitory properties of SCns were also observed in vivo in a rabbit model of PVL-induced endophthalmitis. These calixarenes may represent new therapeutic avenues aimed at minimizing inflammatory reactions and necrosis due to certain virulence factors.
PVL (Panton-Valentine leukocidin) and other Staphylococcus aureus β-stranded pore-forming toxins are important virulence factors involved in various pathologies that are often necrotizing. The present study characterized leukotoxin inhibition by selected SCns (p-sulfonato-calix[n]arenes): SC4, SC6 and SC8. These chemicals have no toxic effects on human erythrocytes or neutrophils, and some are able to inhibit both the activity of and the cell lysis by leukotoxins in a dose-dependent manner. Depending on the type of leukotoxins and SCns, flow cytometry revealed IC 50 values of 6-22 μM for Ca 2 + activation and of 2-50 μM for cell lysis. SCns were observed to affect membrane binding of class S proteins responsible for cell specificity. Electrospray MS and surface plasmon resonance established supramolecular interactions (1:1 stoichiometry) between SCns and class S proteins in solution, but not class F proteins. The membrane-binding affinity of S proteins was K d = 0.07-6.2 nM. The binding ability was completely abolished by SCns at different concentrations according to the number of benzenes (30-300 μM; SC8>SC6 SC4). The inhibitory properties of SCns were also observed in vivo in a rabbit model of PVL-induced endophthalmitis. These calixarenes may represent new therapeutic avenues aimed at minimizing inflammatory reactions and necrosis due to certain virulence factors.
INTRODUCTION
Bacterial PFTs (pore-forming protein toxins) are the largest group of toxins, varying in length, structure, subunit stoichiometry and binding specificities [1] , and contribute to virulence through many pathogenic pathways. They can act on cell physiology, tissue integrity and immune response, and cause inflammation that may interfere with antimicrobial treatment [2] . β-Stranded PFTs from Staphylococcus aureus, i.e. α-toxin and bicomponent or bipartite leukotoxins, constitute a subfamily with different cell spectra and ligand affinities [3, 4] . α-Toxin is a β-stranded PFT produced by almost all S. aureus strains and forms homoheptamers in various target cells, including fibroblasts, platelets, certain T-lymphocytes and erythrocytes [5] . It is suggested to be an important factor in the severity of sepsis [6] . Bipartite leukotoxins mainly consist of: (i) γ -haemolysins (HlgA-HlgB and HlgC-HlgB), produced by almost all strains; (ii) LukE-LukD, produced by only one third of strains; and (iii) PVL (Panton-Valentine leukocidin), produced by 2-12 % of strains routinely isolated in hospitals, according to studies in different countries [7, 8] . PVL is associated with primary and necrotizing skin infections such as boils (or furuncles) [9] , and probably contributes to the severity of necrotizing pneumonia [10, 11] , mainly affecting young immunocompetent patients in the community [12] . It is also encountered in the hospital environment [13] . Morbidity and prognosis of these infections are poor, even with appropriate treatment. Overall, staphylococcal leukotoxins associated with methicillin-resistant S. aureus strains are essential factors of the bacteria's virulence [14] . Thus complementary therapy directly interfering with virulence factors may be of value as an auxiliary to antimicrobial agents [15] . Staphylococcal bipartite leukotoxins are composed of the so-called class S (31-32 kDa) and class F proteins (34) (35) that are encoded either by chromosomal or prophage genes [16] . Leukotoxin class S proteins are believed to direct cell targeting by their binding to membranes, allowing subsequent combination with class F proteins [3, 16] . This bipartite binding favours the formation of efficient octamers composed of alternate class S and class F proteins, sufficient to activate cell Ca 2 + channels before transmembrane pores become active [17, 18] . Leukotoxins permeabilize human cells of the myeloid lineage to monovalent cations and water [16, 19] and thereby cause cell death. During this process, the early opening of Ca 2 + channels and Ca 2 + entry (1) S and F proteins independently bind to cell membranes, possibly mediated by a receptor (R s or R F ) for certain compounds (LukS-PV, HlgC and LukF-PV), or subsequent to the binding of class S compound to membranes for others (HlgB). (2) S and F proteins oligomerize to form an octameric prepore. This step is characterized by the opening of an associated Ca 2 + channel. (3) Reconfiguration of S and F proteins leads to deployment of the stem transmembrane domain, which creates a transmembrane pore, permeable to water and monovalent cations, including ethidium and potassium. SCns act on the first step, since they inhibit class S protein binding to cell membranes.
probably contribute to intracellular signalling pathways, and lead to inflammasome activation and granule secretion [20, 21] .
A direct interaction between drugs and toxins has already been described for S. aureus α-toxin [22, 23] , anthrax toxin protective antigen [24] and Clostridium botulinum C2II toxin [25] . Structural determinations of the proteins constituting PVL [26, 27] and α-toxin pores [28] as well as the study of leukotoxin pore stoichiometry [29] have provided useful information on the topology of the pore. Using these data, we selected various molecules having hydrodynamic radii, shapes, symmetries and charges potentially compatible with the lumen of leukotoxins in order to block the pore. Among a series of molecules tested for leukotoxin inhibition, calixarenes in particular showed promising properties. An extensive characterization of the inhibition properties of SCns (p-sulfonato-calix[n]arenes; n, number of benzene rings; Figure 1A and Supplementary Table S1 at http:// www.biochemj.org/bj/450/bj4500559add.htm) on leukotoxin toxicity was performed on model lipid bilayers, in cells and finally in vivo in rabbits. The steps of toxin-mediated pore formation targeted by SCn inhibition were identified ( Figure 1B ). Non-covalent interaction studies by ESI-MS (electrospray ionization MS) and SPR (surface plasmon resonance) allowed the characterization of a direct leukotoxin-SCn interaction in solution.
EXPERIMENTAL Chemicals
CDs (cyclodextrins) were purchased from Fluka and cyclic peptides were produced by EspiKem (Florence, Italy) with 95 % purity. Amphotericin B, melittin and S. aureus α-toxin were from Sigma, and recombinant equinatoxin II was provided by Dr G. Anderluh (Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubjana, Slovenia). The SCns with n = 4, 6 or 8 (SC4, SC6 and SC8, Figure 1A ) were purchased from Acros Organics.
Bacterial strains, vectors and leukotoxin purification

Bacterial strains and vectors
Escherichia coli XL1 Blue [recA1 endA1 gyrA96 thi1 hsdR17 supE44 relA1 lac (F' proAB lacIqZΔM15 Tn10 (tet r )] cells (Stratagene) were transformed with recombinant pGEX-6P-1-leukotoxin genes (GE Healthcare), following site-directed mutagenesis in the case of mutated proteins.
, gal] cells were used for overexpression of the GST (glutathione transferase)-leukotoxin fusion genes, according to the manufacturer's instructions (GE Healthcare).
Protein purification
GST-LukS-PV, GST-LukF-PV, GST-HlgA, GST-HlgB and GST-HlgC fusion proteins were purified in two steps by chromatography on glutathione-Sepharose 4B (GE Healthcare), followed by GST tag removal with PreScission ® protease (GE Healthcare), by cation-exchange chromatography (MonoS ® , GE Healthcare) [30] or hydrophobic-interaction chromatography for HlgB (Resource ISO ® ; GE Healthcare) [31] . Three mutated, but fully functional, proteins, LukS-PV G10C, Cys-Nter LukF-PV and Cys-Nter HlgA, were fluorescein 5-maleimide labelled (Molecular Probes) and LukS-PV*, LukF-PV* and HlgA* were used to study the binding abilities of toxins to hPMNs (human polymorphonuclear leucocytes) [3] . Homogeneity of purified proteins was verified by SDS/PAGE (10-15 % gels), and molecular masses and integrity were verified under denaturing conditions by ESI-MS. Mass measurements were found to be in agreement with those calculated from their respective amino acid sequences taking into account the additional peptide resulting from the GST fusion: GPLGSPEF (GPLGS for HlgC). Protein accession numbers were as follows: LukS-PV and LukF-PV, EMBL X72700; and HlgA, HlgB and HlgC, EMBL X81586.
Cell assays
Haemolytic assays
The haemolytic activity of HlgA-HlgB or other toxins was determined by turbidimetry at 650 nm with a microplate reader (UVmax from Molecular Devices) and the SOFTmax software, as described previously [32] . Briefly, rRBCs [rabbit RBCs (red blood cells)] or hRBCs (human RBCs) adjusted to D = 0.1 at 650 nm were added to 96-well microplates containing various concentrations of toxins, inhibitors or both. The time course of haemolysis was followed for 45 min at room temperature (22 • C). The results were expressed as percentages of haemolysis compared with fully lysed RBCs. Alternatively, the percentage of haemolysis was assessed by measuring the absorbance at 410 nm as described previously [30] .
hPMN viability assays hPMNs from anonymous healthy donors were purified from buffy coats (purchased from Establissement Français du Sang, Strasbourg, France) as described previously [33] , and 5×10 5 cells/ml, suspended in 10 mM Hepes, 140 mM NaCl, 5 mM KCl, 10 mM glucose and 0.1 mM EGTA, pH 7.3, were routinely used. To assess the cytotoxicity of SCn rapidly, the hPMN suspension was incubated for 2 h with various concentrations of SC4, SC6 or SC8 (0-10 mM) and 4 μM ethidium bromide. Ethidium uptake, a reference method to detect cell viability based on the loss of plasma membrane integrity of dying cells, was monitored by flow cytometry [34] , and cells were scored as viable when ethidium was negative.
Flow cytometry measurements
A FacSort ® flow cytometer (Becton Dickinson) equipped with a 15 mW argon laser tuned to 488 nm was used for flow cytometry measurements.
Leukotoxin biological activity assays
Pore formation was measured as the penetration of ethidium through the pores using flow cytometry. Variations of intracellular Ca 2 + concentrations were assessed by cell Fluo-3 fluorescence in the presence of 1.1 mM extracellular Ca 2 + of cells previously loaded with 5 μM Fluo-3 (Molecular Probes). Cells were incubated for 10 min with 4 μM ethidium, after which toxins were added in the absence of extracellular Ca 2 + . Ethidium (λ em = 630 nm) or Fluo-3 (λ em = 530 nm) fluorescence was measured using Cell Quest Pro TM software (Becton Dickinson). To evaluate inhibition by SCn, leukotoxins were pre-incubated for 10 min each with various concentrations of SCns (0-300 μM). The results of at least three different donors were averaged and expressed as percentages of the control value (with toxin only). Baseline values were obtained for each series of data from a control without addition of toxin, and were systematically subtracted from the results of experimental assays.
Leukotoxin binding assays
Binding assays were carried out with fluorescein-labelled LukS-PV* at 0.1 or 1 nM, LukF-PV* at 20 nM, and HlgA* at 2 nM in the same conditions as used for non-labelled proteins. The amount of labelled protein bound to the cell surface was measured by flow cytometry as cell fluorescence from FL1, and expressed as the percentage of maximum control. IC 50 values were calculated using SigmaPlot (Systat Software) from fitted curve equations for each independent experiment, from which mean + − S.D. values were calculated.
In analysing the effects of SCn using fluorescence, the possibility that SCn might quench or enhance fluorescence signals was also addressed. No significant fluorescence was associated with hPMNs in the presence of SCn alone. SCn did not significantly quench ethidium or fluorescein. However, SC6, and to a lesser extent SC8, emits autofluorescence when excited at 488 nm. However, because of the very low concentrations of toxins present at the surface of hPMNs and thus toxin-bound SCn, we assumed that both quenching and autofluorescence associated with the SCns were negligible, except for the experiments with SC8 described in Figure 4 where autofluorescence was subtracted from experimental values.
Measurements on model lipid membranes [LUVs (large unilamellar vesicles) and PLMs (planar lipid membranes)]
Liposomes
LUVs were obtained as described previously [35] by extruding a solution of multilamellar liposomes prepared in the presence of 80 mM calcein, pH 7.0, (NaOH). The lipid composition used was DOPC (dioleoyl phosphatidylcholine)/Cho (choline) in a 1:1 molar ratio as it was shown that this composition maximizes toxin activity [40] . Vesicle permeabilization was assayed in a fluorescence microplate reader (Fluostar Galaxy) with excitation and emission filters at 480 and 540 nm respectively. Toxins were serially 2-fold diluted in 10 mM Tris/HCl, 20 mM NaCl and 0.1 mM EDTA, pH 7.0 and dispensed into wells of a 96-well microplate, and 100 μl of calcein-loaded LUVs were added at a final lipid concentration of 5 μM. The time course of calcein release was then recorded for 45 min at room temperature as the increase of fluorescence owing to the dequenching of the released dye, which dilutes in the external medium. Results are expressed as the percentage of calcein release (R%) compared with fully lysed liposomes.
PLM experiments
Solvent-free PLMs were constituted from the lipid DPhPC (diphytanoyl-phosphatidylcholine; from Avanti Polar Lipids) on a 100 μm aperture made in a 25 μm thick Teflon septum separating the two chambers (2 ml volume each), as described previously by Joubert et al. [29] . Macroscopic currents were recorded by a patch clamp amplifier (Axopatch 200; Axon Instruments). A PC equipped with a DigiData 1200 A/D converter (Axon Instruments) was used for data acquisition. The current traces were filtered at 100 Hz and acquired at 500 Hz using the Axoscope 8 software (Axon Instruments). Measurements were performed at room temperature as described previously [36] .
SPR binding measurements
A Biacore X apparatus (GE Healthcare) was used for SPR measurements at 25
• C. Two series of experiments were performed: in the first configuration, the Biacore X was equipped with the CM5 chip to assess directly the interaction between HlgA-HlgB and SCn; in the second configuration, a L1 chip was employed initially to bind liposomes to the surface. For CM5 experiments, the chip surface was first activated by EDC [N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide]/NHS (N-hydroxysuccinimide) chemistry, according to the manufacturer's recommendations. HlgA or HlgB monomers were then fluxed at 5 μl/min on the activated chip and the surface was subsequently passivated by treatment with ethanolamine hydrochloride, as indicated by the manufacturer. Finally, SCn was added at 40 μl/min and binding/dissociation kinetics were recorded. A 100 mM NaOH solution was used to regenerate the chip surface for further SCn interaction experiments. HBS-EP buffer (Biacore) was used to flux the system continuously at 40 μl/min. For L1 experiments, the surface of the chip was conditioned with three consecutive injections at 40 μl/min of 2:3 (v/v) isopropanol/50 mM NaOH, each for 1 min. The same solution was also used for the regeneration of the chip surface upon completion of the experiment. Liposomes constituted of DOPC/Cho at a 1:1 ratio were deposited on both flow cells for 10 min at a low flow rate (1 μl/min). For the remainder of the experiment, a constant flow rate was maintained at 40 μl/min. Toxin pre-incubated with SC4, SC6 or SC8 was then added to the surface of the sample cell and the binding kinetics were further monitored. Running buffer (20 mM Hepes and 140 mM NaCl, pH 7.0) was systematically filtered through a 0.22 μm filter and thoroughly degassed before use.
Non-covalent nanoESI-MS experiments
Non-covalent nanoESI-MS experiments were carried out by diluting the proteins to 5 μM in 300 mM ammonium acetate (pH 7.5) containing a 1:1, 1:2, or 1:5 ratio of SCn. Samples were incubated at room temperature for 5 min prior to analysis. NanoESI-MS analyses were performed on an electrospray time-of-flight mass spectrometer (LCT, Waters) equipped with an automated chip-based nanoESI source (Triversa Nanomate, Advion Biosciences) and a throttling valve allowing the pressure in the first pumping stage of the mass spectrometer to be regulated. These experiments required optimization of the accelerating voltage applied on the sample cone (Vc) and the pressure in the first pumping stage of the mass spectrometer (Pi). This optimizes ion desolvation and transmission, and ensures that non-covalent assemblies remain intact during the ionization/desorption process. The various protein-ligand complexes used were similar. All samples were analysed with the same instrumental settings, i.e. Vc and Pi were set to 120 V and 3.5 mBar respectively. Acquisitions were performed in the positive ion mode after external calibration with the multiple charged ions produced by a 2 μM horse heart myoglobin solution diluted in 1:1 (v/v) H 2 O/acetonitrile acidified with 1 % (v/v) formic acid. Since the molecular masses of ligands were less than 5 % of those of proteins, proteins and complexes were assumed to display similar response factors [37] . On the basis of this assumption, relative abundances of the different species could be deduced from their relative peak intensities. The reproducibility of these estimations was found to be within 2-3 %. Masslynx 4.0 TM (Waters) was used for data processing.
Rabbits and eye injections
Experimental procedures were performed in accordance with the ARVO (Association for Research in Vision and Ophthalmology) statement for the use of animals in ophthalmic and vision research. Permission for animal facilities (n • A67-482-34) was given by the French Ministry of Forests and Agriculture (European Directive 2010/63/EU). Injections were performed in the eyes of New Zealand rabbits as described in Siqueira et al. [38] . Injections (50 μl) of physiological saline solution containing PVL (600 ng) and/or SC8 (30 or 300 μg) were given through the pars plana into the eye vitreous with a 25-gauge needle, avoiding the crystalline lens and retina and slowly removing the needle to prevent a backward flow of toxin under the conjunctiva. Direct funduscopic examination (Heine) was performed 24 h and 48 h after vitreous injections. The observed inflammation stage of annexes and eye anterior chamber was graded as described by Siqueira et al. [38] , and vitreal inflammatory activity of the posterior chamber was graded according to criteria given by Nussenblatt et al. [39] . Briefly, five increasing levels of severity of damage were defined: 0, normal eye without vitreous haze; 1, vitreous haze allowing observation of the optic nerve and retinal vessels; 2, vitreous haze still allowing observation of vessels and optic nerve, but with difficulty; 3, vitreous haze allowing observation of the optic nerve only, its boundaries being blurred; and 4, vitreous haze preventing observation of the optic nerve. Standardized criteria allowed us to grade the severity of damage to the anterior chamber and its annexes in five levels: 0, normal eye with no physical damage; 1, a slight conjunctival hyperaemia located around the site of injection;
Table 1 Screening of molecules with potential inhibiting ability
The first column shows molecules tested for inhibition of the activity of various doses of γ -haemolysin HlgA-HlgB or the S. aureus α-toxin. At the concentrations of HlgA-HlgB used (2 and 1 nM), erythrocyte lysis was 100 %, 1 nM being the minimal dose able to induce 100 % haemolysis. The IC 50 μM columns show the concentration of the inhibitory molecules able to protect 50 % of rRBCs from hemolysis. n.i., non-inhibiting toxin activity up to 500 μM concentration. 2, the presence of conjunctival hyperaemia involving at least half of the surface and associated with a scant discharge, but without haze in the anterior chamber; 3, moderate secretion, slight blepharitis, total conjunctival hyperaemia, perikeratic injection, chemosis and slight haze of the anterior chamber, still allowing observation of the iris; 4, total conjunctival hyperaemia, blepharitis and oedema, chemosis, secretion with significant haze of the anterior chamber preventing the observation of the iris. The global inflammatory score represents the sum of the two grades obtained for each eye segment separately and averaged from scores from at least four eyes.
Statistical analysis
A bilateral non-parametric Mann-Whitney U test was used for comparative analysis of inflammatory score of eyes injected with saline and eyes injected with SC8 only. A unilateral nonparametric Mann-Whitney U test was used for comparative analysis of inflammatory score of eyes injected with PVL and eyes injected with PVL and SC8. A threshold P value of <0.05 was set for statistical significance. Statistical analysis was performed using GraphPad Prism ® version 5.04 for Windows (GraphPad Software).
RESULTS
A screening of cyclic molecules enables the promotion of calixarenes to leukotoxin inhibitors
The screening of several cyclic compounds (SCns) (Supplementary Figure S1 at http://www.biochemj.org/bj/450/bj4500559add. htm), CDs (cyclodextrins), and newly designed cyclic peptides c(GF)3, c(GF)4 and c(KD)3, with a hydrodynamic diameter compatible with the pore of leukotoxin HlgA-HlgB, was achieved on rRBCs and liposomes. Cyclic peptides were chosen on the basis of amino acids merging in the trans side of a theoretical HlgAHlgB pore [19] . The inhibitory levels clearly selected SC6 and SC8 as anti-leukotoxin candidates (Table 1 and Figure 2A ). The most effective of the three SCns tested was SC8. Micromolar concentrations of SC8 were sufficient for a complete inhibition of HlgA-HlgB activity on rRBCs. SC6 was as efficient as SC8, but SC4 and cyclic peptides were good inhibitors only at concentrations higher than the micromolar range. (B) Calcein release from 100 nm unilamellar liposomes induced by HlgA-HlgB in the presence of SCns or cyclic peptides. γ -haemolysins were added at 12.5 nM each, and SCns or cyclic peptides were serially 2-fold diluted, as represented on the x axes. The percentage of release was determined with a microplate reader after 45 min of interaction with liposomes whose composition was DOPC/Cho at 1:1 molar ratio. The points at concentration zero show the activity of HlgA-HlgB without inhibitors (controls). The lipid concentration was 5 μM in all experiments. The points are means + − S.E.M. of at least two experiments. CDs did not significantly affect the overall calcein release, whereas HlgA-HlgB activity was strongly inhibited by SC6 and SC8. The cyclic peptides c(GF)3 and c(GF)4 also inhibited calcein release induced by HlgA-HlgB, but at concentrations 10-fold higher than SCn. The IC 50 values were 26 μM for c(GF)4, 3 μM for SC6 and 6 μM for SC8.
Anti-haemolytic activities of molecules against HlgA-HlgB on hRBCs
CDs, either unmodified or bearing hydroxypropyl groups, did not block HlgA-HlgB activity (Table 1 and Figure 2A ). c(GF)4, one of the cyclic peptides tested, showed a significant inhibitory activity on HlgA-HlgB with an IC 50 value comparable with that obtained on staphylococcal α-toxin. However, among the peptides tested, SC6 and SC8 showed stronger inhibiting activities on the leukotoxin at concentrations nearing 1 μM, whereas they were >100-fold less effective against α-toxin. SC4 and cyclic peptides could be considered as inhibitors only at micromolar concentrations ( Figure 2A ). The most effective cyclic peptide was approximately 100-fold less effective than SC8 in completely blocking rRBC lysis.
Inhibition of leukotoxin pore-forming activities on synthetic membranes
When inhibition was conducted in unilamellar liposomes [40] , SCn and c(GF)n were tested against a HlgA-HlgB concentration ( Figure 2B ) that provoked 70 % calcein release. The concentrations necessary to reduce the toxin activity by 50 % (IC 50 ) were 26 μM for c(GF)4, 3 μM for SC6 and 6 μM for SC8, and close to 200 μM for SC4 ( Figure 2B ). The inhibition effects of SC6 and SC8 are different on rRBCs (Figure 2A ) and on liposomes ( Figure 2B ). This is a significant difference, especially for rRBCs (t test, P <0.05), but it should be underlined that inhibition activity on to liposomes is one logarithmic magnitude lesser than that on to RRBCs.
Assessment of SCn toxicity on hRBCs and hPMNs
SC4 and SC8 were not significantly haemolytic on hRBCs up to a concentration of 512 μM, in agreement with Da Silva et al. [41] , although 50 % haemolysis was reached on hRBCs with 141 μM SC6 (Table 1) . Despite haemolytic activities not being observed so far, one cannot exclude an active contaminant in SC6.
Concentrations of up to 1 mM of SCn had no cytotoxicity against hPMNs ( Table 1) . Assessment of both cell size and granularity showed an absence of hPMN activation by any of the SCns tested at concentrations up to 1 mM, and would probably not induce any adverse immune response in hPMNs. Free SCn did not affect liposome stability.
Inhibition of HlgA-HlgB pore-forming activity by SCn on PLMs
SCns were able to interfere with HlgA-HlgB pores on PLMs. SC6 and SC8 present in the solution prior to addition of the toxin completely abolished pore formation ( Figure 3A) . By contrast, SCn added during pore insertion had little or no effect on the increase in ionic current. Thus SCn may operate by reducing the binding of toxins to the lipid bilayer or by direct blockage of formed pores by entering the pore lumen. At − 100 mV, SC6 and SC8 only reduced the ionic current to 25 % and 35 % respectively ( Figure 3B ). This effect cannot justify a full protection of hRBCs and liposomes. Such a contribution may eventually be very small, since LUVs and hRBCs do not have any transmembrane potential to force SCn to enter the lumen of the toxin pore. Furthermore, no significant effect was detected when SCns were added on the trans side of the pore (results not shown). Therefore SCns probably act on steps occurring prior to membrane permeabilization by the leukotoxin(s).
Inhibition of pore formation and Ca 2 + fluxes into hPMNs
As shown previously, entry of ethidium into hPMNs is detected within 5 min after addition of γ -haemolysins (HlgA-HlgB and HlgC-HlgB) or PVL, and accelerates to reach a plateau within 45 min [3] . The PVL-induced ethidium entry into hPMNs observed in the present study was significantly delayed by 30 μM SC8 (Supplementary Figure S1A) . Increasing concentrations of SC8, SC6, and to a lesser extent SC4, were able to increase the lag time before the detection of an ethidium influx as well as decrease/abolish leukotoxin-induced ethidium entry into hPMNs. The SC6 IC 50 values for inhibiting toxin-induced ethidium entry were: 18 μM, 6 μM and 63 μM for HlgA-HlgB, HlgC-HlgB and LukS-PV-LukF-PV respectively (Table 2) . Compared with SC6, the IC 50 values for SC8 were significantly decreased to 22 μM against PVL (P < 0.05, Student's t test). We also tested whether calixarenes were able to bind hPMN membranes and thereby initiate the inhibition of further leukotoxin binding. After application of SCn at 100 μM to hPMNs, followed by several washing steps, the application of leukotoxins at the above concentrations induced pore formation at levels comparable with controls (results not shown). As the result of S and F class protein oligomerization, leukotoxins induced a rapid Ca 2 + entry into hPMNs, independently of pore formation [31] . γ -haemolysinsor PVL-induced Ca 2 + entry into hPMNs was also inhibited by SCn in a concentration-dependent manner (Supplementary Figure  S1B) . Interestingly, SC6 and SC8 stably and totally inhibited ethidium and Ca 2 + entries induced by γ -haemolysins and PVL at comparable concentrations for at least 2 h after incubation of hPMNs with the tested drugs and toxin ( Table 2) . A 6-to >70-fold higher concentration of SC4 compared with SC6 or SC8 was required to obtain such leukotoxin inhibitions. Of the three SCns tested, SC8 displayed the highest inhibitory activity towards the leukotoxins tested, whereas γ -haemolysins were more sensitive than PVL to SCn inhibition.
Inhibition of leukotoxin binding to hPMN membranes
We next determined whether SC8 acts directly on the binding of HlgA and LukS-PV to hPMN membranes. The behaviour of SCn with HlgC was assumed to be similar to that of LukS-PV, since these proteins were reported to share the same binding site at the surface of hPMNs [3] as well as a 76 % amino acid identity. HlgB was not tested, since it cannot bind to hPMN membranes alone [42] . The binding of leukotoxins to hPMN membranes was monitored by flow cytometry, as cell-associated fluorescence of fully functional fluorescein-labelled HlgA*, LukS-PV* or LukF-PV*. We previously reported dissociation constants (K d ) of 0.07 nM and 2.5 nM for LukS-PV* and LukF-PV* to hPMNs respectively [33] . After the addition of labelled HlgA* (2 nM), LukS-PV* (0.1 nM) or LukF-PV* (5 nM) to hPMNs, cell surface fluorescence rapidly increased, tending toward a maximum, with an equilibrium reached within 30 min. Thus, at the concentrations tested, SC8 binding (IC 50 ) was 1.1 μM, 23 μM and 264 μM for fluorescein-labelled HlgA*, LukS-PV* and LukF-PV* respectively ( Figure 4A ). Inhibition of binding was studied under three conditions: (i) SC8 (300 μM) was incubated for 10 min with labelled protein (100 μM) and Table 2 SCn cytotoxicity on RBCs and leukotoxin inhibition (A) Lytic activity of SC4, SC6 and SC8 was assessed (i) in hRBCs as limit concentrations necessary to produce 5 % and 50 % haemolysis, and (ii) estimated in hPMNs as the minimal concentration of SCn necessary for ethidium staining greater than 5 % of that observed in controls without SCn. (B) Inhibition by SCn of lysis or activation of hPMNs by leukotoxin was assessed by determination of IC 50 values of SC4, SC6 and SC8 (in μM) for ethidium (n = 3) and calcium (n = 2) entry into the cells. subsequently added to hPMNs, (ii) the two agents were added simultaneously to hPMNs, and (iii) SC8 was added 15 min after incubation of the labelled protein with hPMNs. With the class S proteins HlgA* and LukS-PV* ( Figures 4B and 4C ), preincubation or simultaneous addition of SC8 abolished the increase in fluorescence. SC8 prevented these proteins from binding to hPMN membranes, even without prior incubation. When SC8 was added after 15 min of incubation of labelled protein with hPMNs, the HlgA* fluorescence notably declined by 95 % within 1 min ( Figure 4B ). For LukS-PV*, the fluorescence decreased to below 10 % of maximum fluorescence ( Figure 4C ). SC8 displaced both bound HlgA* and LukS-PV* from membranes.
LukF-PV* binding was only slowed by SC8, but not reversed or prevented ( Figure 4D ). The addition of SC8 15 min after LukF-PV* addition caused a short, transitory and somewhat unexplained decrease in fluorescence, which then rose to a maximum. Thus LukF-PV* does not appear to be released from membrane complexes by SC8. These experiments nonetheless indicate that SC8 not only inhibits the binding of class S proteins to hPMN membranes, but also reverses it.
Effect of SC8 on PVL
The effect of SC8 on LukS-PV-LukF-PV prepores and pores formed on hPMNs was further assessed. Labelled LukS-PV G10C* and ethidium fluorescence were simultaneously measured as markers of LukS-PV binding and PVL pore formation respectively (Supplementary Figure S2 at http://www.biochemj. org/bj/450/bj4500559add.htm). Fluorescein fluorescence rapidly reached a maximum within 30 min, reflecting LukS-PV G10C* binding to hPMN membranes (Supplementary Figure S2A) . When an effective dose of SC8 (300 μM) was added to hPMNs 5 min after introducing the toxin, bound fluorescein fluorescence rapidly decreased from 41 % to 27 %, and then stabilized thereafter (Supplementary Figure S2A) . This initial decrease in fluorescence may be due to the dissociation of some of the LukS-PV G10C* from hPMN membranes by SC8, prior to being integrated in a S-F oligomer. The stable fluorescence observed thereafter furthermore indicates that the free LukS-PV* in solution is unable to further bind membranes, possibly owing to the formation of LukS-PV G10C*-SC8 complexes. The remaining fluorescence could be that of LukS-PV G10C* involved in membrane-associated functional oligomeric pores or prepores. Indeed, the fluorescence was not eliminated by SC8, in contrast with LukS-PV G10C* alone (Supplementary Figure  S2B) , and PVL oligomers were not removed from membranes by SC8. Figure S2B) .
Figure 5 NanoESI-MS characterization of leukotoxin-SCn interactions
(a-h) Characterization of LukS-PV-SCn interactions. LukS-PV was incubated at 5 μM (a) alone or in the presence of (b) 10 μM SC8, (c) 10 μM SC6 (d) 10 μM SC4, (e) 10 μM SC4 plus 10 μM SC6 or (f) 10 μM SC6 plus 10 μM SC8. Binding specificity was assessed by using 5 μM LukF-PV (g) alone or in the presence of (h) 10 μM SC8. (i) Summary of binding experiments. Each class S protein (5 μM) was incubated in the presence of 10 μM SCn. I P and I PL correspond to peak intensities of unbound proteins and 1:1 protein-ligand complexes respectively. , LukS-PV; , LukF-PV; , SC8; , SC6; and ᭛, SC4. * Corresponds to non-specific 1:2 protein-ligand complexes, for which relative intensities were smaller than 3 % of that of the 1:1 complex in all experiments. All experiments were performed in a 300 mM ammonium acetate buffer (pH 7.5) with identical instrumental parameters (Vc = 120 V, Pi = 3.5 mbar). Deconvoluted mass spectra were obtained using the Maxent 1 algorithm of Masslynx 4.0.
Leukotoxin-SCn interactions: characterization of the leukotoxin-SCn interaction by nanoESI-MS and SPR
Non-covalent nanoESI-MS was used to test whether SCn interacts directly with class S proteins in solution. LukS-PV (5 μM) was incubated in the presence or absence of 10 μM of SC8, SC6 or SC4, and then analysed by nanoESI-MS (see the Experimental section) (Figure 5a ). Under non-denaturing conditions in the absence of SCn, a unique species with a molecular mass of 33 100 + − 1 Da was detected, confirming the monomeric state of the isolated protein. In the presence of SC8, an additional species was observed with a molecular mass of 34 589 + − 1 Da, corresponding to a complex between LukS-PV and SC8 at a 1:1 ratio (Figure 5b) . Similarly, in the presence of SC6 or SC4 (Figures 5c and 5d respectively) , LukS-PV-SCn complexes were detected. The relative intensities of 1:1 complexes signals suggest that LukS-PV displayed a higher affinity for SC8 than for SC6 and SC4. Direct in-solution competition experiments were performed to compare the relative affinities of these different SCns for LukS-PV. Indeed, assuming that relative peak heights faithfully reflect relative abundances of the complexes in solution, this approach allows the different ligands to be ranked according to their relative in-solution affinity for the target protein. Practically, LukS-PV (5 μM) was incubated in an equimolar mixture of SC6 and SC4 (10 μM each). Three species were detected corresponding to the unbound protein, the 1:1 LukS-PV-SC4 complex and the 1:1 LukS-PV-SC6 complex (Figure 5e ). The relative peak heights suggest that SC6 displayed a higher affinity than SC4 for LukS-PV. In a similar experiment with SC6 and SC8 (Figure 5f ), the affinity of LukS-PV appeared clearly higher for SC8 than for SC6, leading to the following affinity ranking: SC8>SC6>SC4, in agreement with their relative inhibitions determined on target cells by flow cytometry experiments. Similar experiments with other class S proteins, i.e. HlgA and HlgC, revealed binding to SCn for both proteins (Figure 5i ). Direct competition experiments resulted in the same affinity ranking for the SCns as determined for LukS-PV (results not shown). Class S proteins could also be ranked according to their relative affinity for SCn (Figure 5i ): for all SCns, the ranking was HlgA>HlgC>LukS-PV. These findings are in general agreement with leukotoxin inhibition IC 50 values (Table 2 ) and membrane-binding capacity as determined above. The ninding specificity of the SCns to class S proteins was also studied. Preliminary control experiments were performed with the class F protein of the PVL, i.e. LukF-PV. Under nondenaturing conditions, a single species was detected in the LukF-PV sample with a molecular mass (35 234 + − 1 Da) corresponding to the monomeric LukF-PV ( Figure 5G ). Interestingly, incubation of LukS-PV and LukF-PV in equimolar concentrations (15 μM each) led to the detection of both proteins as monomers, which also confirms that S and F compounds are not able to oligomerize in the absence of an adequate membrane (results not shown). LukF-PV/SCn mixtures were also prepared and analysed in exactly the same conditions as those used for LukS-PV. With SC8, the best ligand for LukS-PV, almost no complex was detected with the class F protein of the PVL (Figure 5h ), nor with HlgB (results not shown). Similar results were obtained for both SC6 and SC4. Again, almost no complex was detected between HlgB and any of the SCns (results not shown). These analyses confirm that SCn specifically recognizes class S proteins, but not class F proteins.
Direct interaction between γ -haemolysins and SCn was also measured by SPR. The surface of CM5 chips (Biacore) were covalently covered with γ -haemolysin monomers and SCns were subsequently injected, after which protein-SCn interactions were assessed. The resonance response increased with increasing SCn concentrations (Figure 6 ), except for SC4 ( Figure 6C ), for which binding was almost negligible even at the highest concentrations tested (100-1000 μM, Figure 6C) . A dose-dependent increase in the resonance response clearly appeared for SC6 ( Figures 6A  and 6B) , with the latter bound with a higher affinity to the HlgA monomer than to HlgB. Similar results were also obtained for SC8. The magnitude of the responses at the highest concentrations of SC6 used ( Figure 6 ) also indicates that more than one molecule of SC6 was bound to the protein when the SC concentration was over 10-15-fold the equimolar ratio [theoretical responses for 1:1 interaction of SC6 with HlgA or HlgB are 113 R.U. (resonance units) and 34 R.U. respectively], with shapes of sensorgrams not in accordance with a 1:1 interaction. Although the kinetic constants for the binding of SCn to γ -haemolysins were not performed, SPR experiments nevertheless confirm that SC4 affinity for γ -haemolysin monomers was weak, whereas SC6 and SC8 directly bound to HlgA monomer with high affinity and with a stoichiometry of up to three SCn molecules per HlgA molecule. These SPR experiments indicate a 1:1 HlgA/SCn stoichiometry at low SCn concentrations, whereas, at very high SCn concentrations (10:1 or 15:1 molecular ratios), additional inhibitor molecules were bound to HlgA, consistent with SCn binding to non-specific sites on the protein. By contrast, SC6 and SC8 bound to HlgB only if present at very high concentrations.
We further investigated the binding of leukotoxins to membranes in a liposome model by means of SPR. The HlgAHlgB combination was used as toxin, the latter being the most active leukotoxin on DOPC/Cho (1:1 mol) liposomes [43] and the leukotoxin most sensitive to SCn. Only the simultaneous presence of both components of the pore resulted in a stable insertion into the membrane in this system. When SCns were added together with the toxin, toxin binding to the lipid membrane was lower than in the absence of SCn. The effects of SC6 and SC8 were similar (Supplementary Figure S3 Figure S3C) . Hence the main inhibitory action upon binding of HlgA or HlgC, i.e. the class S component rather than the class F component, was confirmed.
Effect of SC8 in a rabbit model of PVL-induced endophthalmitis
Several leukotoxins have been reported to cause severe endophthalmitis in a rabbit eye model [44] , even in the absence of the bacteria [45] . The effectiveness of SC8 was hence tested after intravitreous injection of PVL in a rabbit non-infectious model. Double-blind readings for injection of 50 μl of physiological solution containing 600 ng of PVL was used as a control, and showed a reaction level 0 in the anterior and posterior chambers 24 h and 48 h after injection (see the Experimental section for scoring methods; the sum of inflammatory scores are summarized in Figure 7 ). The inflammatory scores at 24 h and 48 h after injection of 30 μg or 300 μg of SC8 were not significantly different from the controls. Nevertheless, after 48 h, injection of 300 μg of SC8 slightly increased the sum of inflammatory score from 0.5 to 1.6 (n = 5). Injection of 600 ng of PVL induced a very strong inflammatory reaction, with a mean inflammatory score of 3.5 in the anterior chamber at 48 h, hiding the posterior chamber (assumed score = 4). The simultaneous injection of PVL plus 30 μg of SC8 significantly reduced (24 h, P < 0.05; 48 h, P < 0.01, one-tailed) the inflammation scores below 1.6 (n = 5). The injection of the higher dose of SC8 (300 μg) together with PVL significantly reduced the inflammation scores (0.8, n = 5) compared with PVL only (24 h, P < 0.05; 48 h, P < 0.01, one-tailed), which was very close to that of the negative control. Of particular note, the inflammation of eyes injected with PVL increased with time, whereas the addition of SC8 conversely reduced inflammation between 24 h and 48 h.
DISCUSSION
The chemical inhibition of bacterial toxins is an already existing concept with the Vibrio cholerae toxin [46] , E. coli LT toxin [47] and Clostridium difficile toxin [48] . S. aureus expresses families of toxins in which members are similar in structure and activities, despite differences in sequence, cell tropism and most likely receptors. This is especially the case for staphylococcal enterotoxins and leukotoxins. Enterotoxins display selective T-lymphocyte clone specificity, whereas leukotoxins exhibit a broader cell specificity with different serotypes of toxins and binding sites [49] . Such characteristics probably contribute in allowing S. aureus to evade host immune memory. Leukotoxins are associated with a large variety of staphylococcal diseases and may therefore be valuable targets for therapeutic drugs.
In the present study, human hPMNs exposed to commercial SC6 or SC8 remained viable without modification of morphology or granularity. At concentrations below 1 mM, the SCn tested did not show any toxic activity against human erythrocytes or hPMNs, nor in the Ames test [50] , despite the fact that SC6 initiated haemolysis at concentrations above 512 μM. The low toxicity observed for SCn solutions above 1 mM may also be due to contaminating molecules. SCns, especially SC4, have previously been reported to be poor antigens [51] . In most cases, the concentrations of SCn toxic for cells were at least 4-5-fold greater than the doses sufficient to inhibit leukotoxins (SC6 compared with PVL being an exception). These SCns inhibit haemolysis caused by γ -haemolysin at concentrations 10 3 -10 5 -fold lower than those necessary for standard osmotic protectants, which is approximately 30 mM [52] . Although the initial choice of potential inhibitors was targeted at molecules able to approximately accommodate within the upper ring of leukotoxin pores, further analysis led us to suspect SCn as operating in a different manner. The interaction of SCn with leukotoxins, either soluble or inserted in membranes, is specific for class S compared with class F proteins composing leukotoxins. Electrostatic rather than purely steric interactions probably explain their activity. SC6 and SC8 were 100-fold less active in inhibiting α-toxin than γ -haemolysin, two related PFTs (Table 1) . Because of the very low experimental concentration of leukotoxins, assessment of inhibition using cell models was mostly achieved in the presence of BSA. BSA may capture some SCns [53] , thus increasing the working concentration of SCn, which may represent conditions closer to those in vivo.
Observations in erythrocytes, synthetic membranes, and hPMNs (Table 2, Figures 2 and 3 , and Supplementary Figures  S1 and S2) indicate that a 5000-10 000-fold molecular excess of commercially available SC8 (or SC6) was necessary to obtain 100 % inhibition of leukotoxins, including PVL which remained the least sensitive leukotoxin to the studied SCn. The IC 50 value of SCn on PVL was higher for Ca 2 + than for ethidium entry. Inversely, with HlgA-HlgB and HlgCHlgB, the IC 50 value was higher for ethidium than for Ca 2 + entry ( Table 2 ). Concentrations of commercial SC6 or SC8 between 30 and 100 μM were sufficient to completely abolish the biological activity of leukotoxins. At similar concentrations, both abolished: (i) pore-dependent lytic activity against RBCs and hPMNs (Supplementary Figure S2A) ; (ii) Ca 2 + entry into hPMNs that is dependent on at least a prepore or a non-finalized pore (Supplementary Figure S2B) ; and (iii) changes in cell morphology. In addition to inhibiting S monomer binding to membranes, SCns dissociated leukotoxin S monomers bound to cell membranes ( Figure 4 ). Such inhibition of toxin binding to the cell surface was observed for at least 30 min. If the tested SCn was added to previously opened pores, leukotoxins were not significantly affected ( Figure 3B ). In fact, SC8 added after 5, 10, 15 or 20 min of incubation of hPMNs with PVL abrogated the increase in fluorescence associated with pore function (Supplementary Figures S3A and S3B) . Thus, although SCns as such have no noticeable impact on cell viability, they partially destabilize already formed pores as well as prevent the formation of new pores. ESI-MS and SPR confirmed that SCns directly bind to leukotoxin S proteins, but not to cell membranes, and have a negligible interaction with F components. More specifically: (i) there was a direct interaction between class S proteins and SCns, in contrast with class F proteins; (ii) a 1:1 protein/ligand binding stoichiometry of these complexes was revealed; (iii) SCns were classified according to their relative affinity for various class S proteins; and (iv) SCns probably have different relative affinities according to class S proteins and SCn. Although the three-dimensional structures of class F proteins and α-toxin are similar to those of class S proteins, class S components probably generate direct and stronger interactions with SCn. In fact, SC6 and SC8 bear certain properties of non-competitive inhibitors, mostly because they can destabilize already-bound class S proteins. However, it remains unclear whether SCns engage a denaturation of proteins; thus, evidence of the interaction site in leukotoxins remains mainly lacking.
Certain electrostatic interactions have been reported between SC6-lysyl oxidase, the sulfonate group and the lateral chains of the active site of the enzyme [53, 54] . However, the reported IC 50 value is approximately 1000-fold higher than the effective concentration observed in the present study for γ -haemolysins. SC4 interacts strongly with BSA at three non-equivalent binding sites [55] , although the strength of the interactions between SCn and BSA is inversely proportional to the size of the macrocyclic calixarene ring [53] . Consequently, the mechanism of the interaction between SCn and HlgA, HlgC or LukS-PV is undoubtedly different to that found between SCn and BSA. Interaction between SC6 or SC8 and the prion pathogenic protein PrP SC has been described [53] and increases with ring size [54] . A SC8 derivative has been shown to interact with anti-thrombin and heparin cofactor II peptides through electrostatic interaction with a series of basic residues [53] . In the rim domain of staphylococcal leukotoxins, such clusters of arginine/lysine residues are also present, although these are present in both class S and class F proteins.
In conclusion, SC6 and SC8 inhibit most staphylococcal poreforming toxins by specifically preventing the binding of class S proteins to membranes ( Figure 1B ). This inhibition is effective in vivo in completely decreasing the inflammatory reaction due to the injection of leukotoxins. Inhibition experiments with hPMNs and nanoESI-MS indicate that SCns may act by binding to class S components, inhibiting their binding to either membranes or the F component and thereby preventing pore formation. Moreover, the injection of SC8 was not significantly inflammatory and was able to considerably reduce the inflammation induced by 600 ng of PVL in rabbit eyes. SCns are thus potentially interesting in light of the importance of these toxins in contributing to the virulence of one of the most common bacterial pathogens. In human cases of staphylococcal endophthalmitis (∼ 80 % of endophthalmitis cases) [56] , eye sterilization is usually achieved, although the major problem remains vision recovery since eye inflammation is destructive. In such cases, SCns and/or specific derivatives could be pertinent auxiliaries to antibiotics, where they can interact with several of these parent pore-forming toxins. . SC8 is able to destabilize part of fluorescent PVL previously bound to membranes, but its interaction provokes an arrest of the whole ethidium cell content (A). Ethidium uptake was also considered (B). In the absence of SC8, the fluorescence of hPMNs incubated with PVL rapidly increased to reach a plateau within 30 min. The addition of 300 μM SC8 after 5 min resulted in a stabilization of the slope of ethidium uptake by the hPMNs to a constant 1.5 + − 0.2 % per min, whereas the control without SCn reach a maximum slope of 4.3 + − 0.4 % per min. These results again indicate that addition of SC8 prevents the formation of new functional oligomers. The addition of SC8 after 5, 10, 15 or 20 min ( Figure S3B ) gave similar results: ethidium uptake was almost stopped, and ethidium entry remained low and constant (between 0 and 1.7 % per min). SC8 cannot easily access LukS-PV already engaged into a pore, but may not favour further entry of ethidium through pores that have been formed. Figure: in the absence of SCn, HlgA bound to liposomes quickly and in large amounts, but was subsequently desorbed almost completely (approximately 90 %) from the membrane (A, grey line). By contrast, approximately 50 % of initially adsorbed HlgB was retained (B, grey line). When both HlgA and HlgB components were added together (C, grey line), the binding signal was larger than the sum of those for each component independently added; the aggregate was stably retained on the membrane, whatever the physico-chemical conditions. This experiment was repeated at least three times with DOPC/Cho liposomes and gave consistent results. *This value comes from the particular conformation of calix [8] , where the arene units are up and down (so that to give an almost double value of height if compared with calix [4] and calix [6] arene, which have a more rigid conformation. For more information, see [1] .
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